Purpose To describe the efficacy of intravitreal aflibercept on 12-month visual and anatomical outcomes in patients with neovascular age-related macular degeneration (AMD) recalcitrant to prior monthly intravitreal bevacizumab or ranibizumab. Methods Non-comparative case series of 21 eyes of 21 AMD patients with evidence of persistent exudation (intraretinal fluid/cysts, or subretinal fluid (SRF), or both) on spectral domain OCT despite Z6 prior intravitreal 0.5 mg ranibizumab or 1.25 mg bevacizumab (mean 29.8±17.1 injections) over 31.6±17.4 months who were transitioned to aflibercept. Results At baseline, best-corrected visual acuity (BCVA) was 0.42 ± 0.28 logarithm of minimum-angle of resolution (logMAR), central foveal thickness (CFT) was 329.38 ± 102.67 mm and macular volume (MV) was 7.71±1.32 mm 3 . After 12 months of aflibercept (mean 10.2±1.2 injections), BCVA was 0.40±0.28 logMAR (P ¼ 0.5), CFT decreased to 292.71 ± 91.35 mm (P ¼ 0.038) and MV improved to 7.33 ± 1.27 mm 3 (P ¼ 0.003). In a subset of 15 eyes with a persistent fibrovascular or serous pigment epithelial detachment (PED), mean baseline PED greatest basal diameter (GBD) was 2350.9±1067.6 mm and mean maximal height (MH) was 288.7±175.9 mm. At 12 months, GBD improved to 1896.3 ± 782.3 mm (P ¼ 0.028), while MH decreased to 248.27 ± 146.2 mm (P ¼ 0.002).
Introduction
Some eyes with neovascular age-related macular degeneration (AMD) have persistent disease activity despite monthly therapy. 1 Various strategies have been attempted in eyes including increasing the frequency of dosing 2 by alternating treatment between ranibizumab and bevacizumab or increasing the dose of the drug while maintaining a monthly regimen. 2 Efforts have also focused on switching these eyes to aflibercept. [3] [4] [5] [6] In this case series review, we analyze the visual and anatomical changes following 12 months of intravitreal aflibercept in previously treated patients with recalcitrant exudative-AMD.
Case series
This was an interventional, IRB approved, noncomparative case series of consecutive patients with neovascular AMD that were switched from treatment with intravitreal ranibizumab or bevacizumab to intravitreal aflibercept for recalcitrant exudative-AMD defined as choroidal neovascularization secondary to AMD with spectral domain OCT (SD-OCT; Heidelberg Spectralis HRA þ OCT, Vista, CA, USA) documentation of subretinal fluid (SRF) and/or intraretinal fluid (IRF) and/or subretinal pigment epithelium (RPE) fluid with adjacent SRF/IRF following 46 months of monthly anti-VEGF treatment. Idiopathic polypoidal choroidal vasculopathy and central serous retinopathy cases were excluded. We excluded eyes with anti-VEGF therapy o28 days prior, photodynamic therapy (PDT) o3 months prior or 44 prior PDT treatments, significant subfoveal-fibrosis (450% of lesion), prior triamcinolone (o6 months), intraocular surgery (o2 months), history of vitrectomy, active intraocular-inflammation, vitreous hemorrhage, subretinal hemorrhage involving 41 disc area of central fovea, previous RPE tear, or best-corrected visual acuity (BCVA) o20/400.
Each subject served as his/her own historical control and was treated by the same physician using identical retreatment criteria (before/after conversion).
Twenty-one eyes of 21 patients (9 males, 12 females; mean-age 80.7 ± 4.5 years) who had received 29.8 ± 17.1 (range 6-70) prior ranibizumab or bevacizumab injections over 31.6 ± 17.4 (range 7-63) months were ). After 12 months of aflibercept (mean 10.2 ± 1.2 injections; range 10-12), BCVA was 0.40 ± 0.28 logMAR (20/50 snellen; range 0-1, P ¼ 0.5, Figure 1a) , CFT decreased to 292.71 ± 91.35 mm (range 193-627, P ¼ 0.038, Figure 1b) , and MV improved to 7.33 ± 1.27 mm 3 (range 5.07-9.36, P ¼ 0.003, Figure 1c ; Table 1A ). There was a reduction in proportion of eyes with persistent SRF (17/21 to 10/21, P ¼ 0.05) and IRF (10/21 to 5/21 eyes, P ¼ 0.2). Figures 2 and 3 are representative case examples of the anatomical response after switching to aflibercept. We analyzed a subgroup of 15 eyes with a persistent fibrovascular or serous pigment epithelial detachment (PED). Using software calipers, we calculated a significant reduction of greatest basal diameter and maximal height both at 6 and 12 months (Table 1B) . None of the eyes in our study developed significant ocular or systemic adverse events.
Discussion
Short-term efficacy of transitioning to aflibercept in such recalcitrant eyes has been reported. [4] [5] [6] [7] [8] [9] Potential explanations for the overall anatomic success of aflibercept therapy in recalcitrant eyes include tachyphylaxis, pharmacogenetics, or the increased binding affinity of aflibercept.
The anatomic gains in our study did not translate into improved visual acuity. This is not surprising, as our patients had received a mean of 29.8 prior injections with persistent exudation. Prior studies have shown that in cases of chronic AMD, conversion from bevacizumab to ranibizumab yielded improvements in anatomy, but not visual acuity. 10 We did not analyze the characteristics of eyes that failed to respond to aflibercept. It is also not yet clear whether similar but earlier intervention with aflibercept could avoid visual acuity loss and whether cases initially unresponsive to aflibercept might show similar responses when switching to another anti-VEGF medication such as ranibizumab. Most patients required monthly aflibercept, more frequent than the bimonthly dosing it is designed for as these were recalcitrant eyes. It is also possible that as we included eyes that had been followed for 12 months on aflibercept, these were cases more responsive, as non-responders may have been switched to another regimen or might elect to abandon treatment. 
